{"filings":[{"id":529157,"accession_number":"0001104659-26-063936","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2026-05-19T21:13:50+00:00","items":["1.01","9.01"],"status":"ready","headline":"RPID raises ~$9M in underwritten common stock and warrant offering; insiders add $140K","event_type":"other_material","confidence":"high","bullets":["Underwritten offering of 3.58M units (share + two warrants) at $1.955/unit; net proceeds ~$8.9M.","Concurrent direct offering to directors/officers of 71,607 shares plus warrants for gross proceeds ~$140K.","Series A warrants: exercise price $1.955, exercisable after 6 months, 1-year term; Series B: $2.34, 5-year term.","Pre-funded warrants: $1.945 purchase price, $0.01 exercise, immediately exercisable until fully exercised.","Proceeds to fund working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":69162,"accession_number":"0001380106-26-000067","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2026-05-13T20:33:24+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rapid Micro Biosystems Q1 revenue up 11% to $8.0M; net loss widens to $14.3M","event_type":"earnings","confidence":"high","bullets":["Total revenue $8.0M (+11% YoY); product revenue $5.6M (+36%).","Net loss $14.3M ($0.31/sh) vs $11.3M ($0.26/sh) in Q1 2025.","Recurring revenue $5.1M (+28%), 63% of total; placed 6 Growth Direct systems (3 in Q1 2025).","Gross margin 4.6% vs 5.6% last year; cash and equivalents $23M.","Reaffirms FY2026 guidance: revenue $37-41M, 30-38 system placements, ~20% gross margin."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103422,"accession_number":"0001380106-26-000045","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"COO John Wilson departs April 10; CEO Spignesi assumes operating role","event_type":"leadership","confidence":"high","bullets":["John Wilson, COO, will leave as of April 10, 2026 for family reasons; no disagreement with the Company.","CEO Robert Spignesi will also serve as principal operating officer effective April 10, 2026.","Separation agreement includes consulting at $200/hr, max 20 hrs/month through June 30, 2026.","Vested stock option exercise period extended to March 31, 2027, with weekly sale cap of 20,000 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103421,"accession_number":"0001380106-26-000029","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Rapid Micro reports record Q4 revenue $11.3M (+37% YoY); 2026 guidance $37-41M; Samsung Biologics expands Growth Direct","event_type":"earnings","confidence":"high","bullets":["Q4 total revenue $11.3M (+37% YoY); product revenue $9.3M (+78%).","FY 2025 revenue $33.6M (+20% YoY); net loss $47.1M ($1.05/share).","FY 2026 guidance: revenue $37-41M, 30-38 system placements, gross margin ~20%.","Samsung Biologics placed multi-system Growth Direct order in Q1 2026, following Amgen's Q4 2025 multi-system order.","Cash position $39M; $25M unused under Trinity Capital debt facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103420,"accession_number":"0001380106-26-000007","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rapid Micro Biosystems pre-announces record Q4 rev $11.3M (+37% YoY); FY rev $33.6M (+20%)","event_type":"earnings","confidence":"high","bullets":["Q4 2025 total revenue expected ~$11.3M, up ~37% YoY; record multi-system order from Top 20 biopharma customer.","Full year 2025 revenue expected ~$33.6M, up ~20% YoY; recurring revenue $17.8M (+15%).","Q4 placed 16 new Growth Direct systems, validated 3 customer systems; full year placed 28 and validated 18.","Cumulative installed base: 190 systems globally, 155 validated.","Company to announce complete FY2025 results and 2026 outlook later in Q1 2026."],"consensus_eps_estimate":-0.227,"consensus_eps_actual":-1.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":33587000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119663,"accession_number":"0001380106-25-000195","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Rapid Micro Biosystems Q3 revenue $7.8M (+3% YoY); raises FY guidance after record multi-system order","event_type":"earnings","confidence":"high","bullets":["Q3 2025 revenue $7.8M (+3% YoY); recurring revenue up 32% to $4.8M on record consumables.","Net loss $11.5M ($0.26 loss per share), flat YoY; gross margin improved to 9% from 8%.","Receives largest multi-system order in company history from existing Top 20 global biopharma customer.","Raises FY2025 revenue guidance to at least $33.0M, assumes at least 27 Growth Direct placements.","Cash and equivalents $42M as of Sept 30, 2025."],"consensus_eps_estimate":-0.2499,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":22305000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136238,"accession_number":"0001380106-25-000169","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["1.01","2.02","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Rapid Micro Biosystems Q2 revenue $7.3M (+10% YoY); enters $45M term loan with Trinity Capital","event_type":"debt","confidence":"high","bullets":["Q2 2025 revenue $7.3M, up 10% YoY; net loss $11.9M ($0.27/sh) vs $12.6M ($0.29) prior year.","Gross margin turned positive at 4% (vs -3% in Q2 2024); recurring revenue up 15% to $4.4M.","Reaffirms FY2025 revenue guidance of at least $32.0M.","Entered $45M term loan facility with Trinity Capital; $20M drawn at close, no financial covenants.","Initial interest rate 11.5% p.a.; 36-month interest-only period; warrants for 179,104 shares at $3.35/sh."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153311,"accession_number":"0001380106-25-000153","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"CEO Robert Spignesi diagnosed with treatable lymphoma; will continue to lead company","event_type":"other_material","confidence":"high","bullets":["CEO Robert Spignesi disclosed a recent diagnosis of a treatable form of lymphoma.","Treatment expected to last approximately four months; doctors gave a good prognosis.","Spignesi will continue to actively lead the business with limited in-person time and travel.","Board and leadership team are fully supportive of his continued role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153310,"accession_number":"0001380106-25-000114","cik":1380106,"company_name":"RAPID MICRO BIOSYSTEMS, INC.","ticker":"RPID","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Director Jeffrey Schwartz resigns from Rapid Micro Biosystems board effective May 22, 2025","event_type":"leadership","confidence":"high","bullets":["Jeffrey Schwartz resigned as director and chair of nominating and corporate governance committee; not due to any disagreement.","Annual meeting elected Dafni Bika, Ph.D. and Inese Lowenstein as Class I directors for terms expiring 2028.","Stockholders ratified PricewaterhouseCoopers LLP as independent auditor for fiscal year ending Dec 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}